title: Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
abstract: Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted; 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations.
authors.affiliation: Department of Haematology, Karolinska University Hospital, Stockholm, Sweden. mats.merup@ki.se
authors.forename: Mats
authors.initials: M
authors.lastname: Merup
authors.forename: Vladimir
authors.initials: V
authors.lastname: Lazarevic
authors.forename: Hareth
authors.initials: H
authors.lastname: Nahi
authors.forename: Björn
authors.initials: B
authors.lastname: Andreasson
authors.forename: Claes
authors.initials: C
authors.lastname: Malm
authors.forename: Lars
authors.initials: L
authors.lastname: Nilsson
authors.forename: Mats
authors.initials: M
authors.lastname: Brune
authors.forename: Katarina
authors.initials: K
authors.lastname: LeBlanc
authors.forename: Jack
authors.initials: J
authors.lastname: Kutti
authors.forename: Gunnar
authors.initials: G
authors.lastname: Birgegård
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002066:Busulfan / Q000627:therapeutic use; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D055728:Primary Myelofibrosis / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D013154:Spleen / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014916:Whole-Body Irradiation / Q000379:methods
chemical_list: D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine